Sugi Predict

Sugi Predict / Compounds / SCHEMBL14239072

SCHEMBL14239072

SCHEMBL14239072

CC(C)(C)OC(=O)N1C=C(OS(=O)(=O)C(F)(F)F)CC1

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ STS P08842 3/20 0.36
▸ GPR119 Q8TDV5 3/20 0.34
▸ ESR2 Q92731 1/20 0.34
▸ RORC P51449 1/20 0.34
▸ NR1H2 P55055 3/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ NR1H3 Q13133 2/20 0.33
▸ F13A1 P00488 1/20 0.33
▸ TGM2 P21980 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1484967 0.93 STS (0.34) STSGPR119ESR2RORCNR1H2
SCHEMBL16335975 0.86 USP2 (0.40) STSGPR119ESR2RORCNR1H2
SCHEMBL12478001 0.83 CXCR2 (0.32) —
SCHEMBL19837061 0.83 RORC (0.34) STSGPR119RORCNR1H2NR1H3
SCHEMBL19837051 0.83 RORC (0.34) STSGPR119RORCNR1H2NR1H3
SCHEMBL212403 0.81 PDK4 (0.46) STSGPR119ESR2NR1H2
SCHEMBL23705507 0.81 CXCR2 (0.33) —
SCHEMBL514282 0.80 STS (0.33) STSGPR119ESR2RORC
SCHEMBL3434214 0.80 STS (0.39) STSGPR119ESR2NR1H2USP2
SCHEMBL431871 0.79 NR1H2 (0.36) STSGPR119NR1H2NR1H3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-01-30 — — US disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 — — EP disclosed
CN-118804917-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-10-18 — — CN disclosed
EP-4441044-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2024-10-09 — — EP disclosed
CN-118302422-A Substituted N-cyanopyrrolidines having activity as USP30 inhibitors 特殊治疗有限公司 2024-07-05 — — CN disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 — — WO disclosed
EP-3350170-B1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-01-26 — — EP disclosed
CN-107921044-B GLS1 inhibitors for the treatment of disease 德州大学系统董事会 2022-01-21 — — CN disclosed
US-20140179682-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-06-26 — — US disclosed
US-20140179682-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-06-26 — — US disclosed
US-20140080798-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-20 — — US disclosed
US-20140073620-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-13 — — US disclosed
WO-2014026243-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-02-20 — — WO disclosed
US-20130324532-A1 FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-12-05 — — US disclosed
US-20130017194-A1 FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-01-17 — — US disclosed
US-20130017194-A1 FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-01-17 — — US disclosed
US-20130017194-A1 FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2013-01-17 — — US disclosed
WO-2012170845-A2 METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF HEFFERNAN MICHELE L R (US) 2012-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130017194-A1 FAK INHIBITORS PTK2, CTTN, SRC STS 4068/4885GPR119 1235/4885ESR2 1903/4885
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS USP30, USP47, USP1 STS 3584/4885GPR119 3625/4885ESR2 3718/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A STS 3212/4885GPR119 399/4885ESR2 1086/4885
US-20130324532-A1 FAK INHIBITORS PTK2, CTTN, SRC STS 4068/4885GPR119 1235/4885ESR2 1903/4885
US-20140080798-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR STS 2135/4885GPR119 418/4885ESR2 1294/4885
US-20140179682-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF GRM5, GRIK5, GRM2 STS 3026/4885GPR119 25/4885ESR2 701/4885
US-20140073620-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR STS 2165/4885GPR119 484/4885ESR2 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.